Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy.
作者信息
Danesh Melissa J, Mulvaney Patrick M, Murakami Naoka, Riella Leonardo V, Silk Ann W, Hanna Glenn J, Schmults Chrysalyne D
机构信息
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Division of Nephrology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
出版信息
Cancer Immunol Immunother. 2020 Sep;69(9):1937-1941. doi: 10.1007/s00262-020-02644-2. Epub 2020 Jun 25.
Abstract
摘要
相似文献
1
Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy.
Cancer Immunol Immunother. 2020 Sep;69(9):1937-1941. doi: 10.1007/s00262-020-02644-2. Epub 2020 Jun 25.
2
Pembrolizumab-induced severe rejection and graft intolerance syndrome resulting in renal allograft nephrectomy.
J Oncol Pharm Pract. 2021 Mar;27(2):470-476. doi: 10.1177/1078155220934160. Epub 2020 Jun 24.
3
Checkpoint blockade after kidney transplantation.
Eur J Cancer. 2018 Jun;96:111-114. doi: 10.1016/j.ejca.2018.03.019. Epub 2018 Apr 26.
4
Safe Administration of An Anti-PD-1 Antibody to Kidney-transplant Patients: 2 Clinical Cases and Review of the Literature.
J Immunother. 2017 Nov/Dec;40(9):341-344. doi: 10.1097/CJI.0000000000000188.
5
Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection
.
Clin Nephrol. 2018 Apr;89(4):252-259. doi: 10.5414/CN109278.
6
Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.
Front Immunol. 2021 Jul 19;12:653437. doi: 10.3389/fimmu.2021.653437. eCollection 2021.
7
Severe Allograft Rejection and Autoimmune Hemolytic Anemia After Anti-PD1 Therapy in a Kidney Transplanted Patient.
Transplantation. 2017 Sep;101(9):e291. doi: 10.1097/TP.0000000000001861.
8
Increased circulating follicular helper T cells with decreased programmed death-1 in chronic renal allograft rejection.
BMC Nephrol. 2015 Nov 3;16:182. doi: 10.1186/s12882-015-0172-8.
9
The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma.
Melanoma Res. 2020 Jun;30(3):321-324. doi: 10.1097/CMR.0000000000000651.
10
Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy.
Am J Transplant. 2016 Aug;16(8):2496-7. doi: 10.1111/ajt.13786. Epub 2016 Apr 21.
引用本文的文献
1
Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits.
Transpl Int. 2024 Nov 25;37:13204. doi: 10.3389/ti.2024.13204. eCollection 2024.
2
Immune Checkpoint Inhibitor Therapy for Kidney Transplant Recipients - A Review of Potential Complications and Management Strategies.
Transpl Int. 2024 Oct 16;37:13322. doi: 10.3389/ti.2024.13322. eCollection 2024.
3
Acute Allograft Rejection in Kidney Transplant Recipients Treated With Immune Checkpoint Inhibitors: An Educational Case Report.
Can J Kidney Health Dis. 2024 Oct 21;11:20543581241289191. doi: 10.1177/20543581241289191. eCollection 2024.
4
Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies.
Front Transplant. 2023 Oct 30;2:1284740. doi: 10.3389/frtra.2023.1284740. eCollection 2023.
5
Allograft rejection following immune checkpoint inhibitors in solid organ transplant recipients: A safety analysis from a literature review and a pharmacovigilance system.
Cancer Med. 2023 Mar;12(5):5181-5194. doi: 10.1002/cam4.5394. Epub 2022 Dec 12.
6
Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates.
Korean J Transplant. 2022 Jun 30;36(2):82-98. doi: 10.4285/kjt.22.0013. Epub 2022 Jun 3.
7
Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?
Front Med (Lausanne). 2022 Jun 14;9:906565. doi: 10.3389/fmed.2022.906565. eCollection 2022.
8
Application of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic Review.
Interdiscip Sci. 2021 Dec;13(4):801-814. doi: 10.1007/s12539-021-00437-4. Epub 2021 Jun 21.
9
Immunotherapy use outside clinical trial populations: never say never?
Ann Oncol. 2021 Jul;32(7):866-880. doi: 10.1016/j.annonc.2021.03.199. Epub 2021 Mar 24.
10
A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.
Kidney Int. 2021 Jul;100(1):196-205. doi: 10.1016/j.kint.2020.12.015. Epub 2020 Dec 24.
本文引用的文献
1
Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020.
Kidney360. 2020 Jan 14;1(2):130-140. doi: 10.34067/KID.0000852019. eCollection 2020 Feb 27.
2
The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Oncologist. 2020 Jun;25(6):505-514. doi: 10.1634/theoncologist.2019-0659. Epub 2020 Feb 11.
3
Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.
J Immunother Cancer. 2019 Apr 16;7(1):106. doi: 10.1186/s40425-019-0585-1.
4
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy.
Int J Mol Sci. 2019 Feb 11;20(3):755. doi: 10.3390/ijms20030755.
5
Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab.
N Engl J Med. 2017 Jan 12;376(2):191-192. doi: 10.1056/NEJMc1614298.
Zotero 插件